Clinical Trial Update: Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating ALTU-238, an extended-release crystalline formulation of recombinant human growth hormone, in adults with growth horm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• ALTU-238 (recombinant human growth hormone)

Snippet

Sponsor: Altus Pharmaceuticals | Conditions: Adult Growth Hormone Deficiency | Phase 2 | Status: COMPLETED